文献速递头颈部肿瘤放疗

PET/CT引导剂量绘画对比CT引导调强放疗在局部晚期鼻咽癌中的研究

PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma.
PubMed 文献 · Radiat Oncol · 2017-01-13

该研究比较了PET/CT引导剂量绘画调强放疗(DP-IMRT)与CT引导IMRT联合化疗在局部晚期鼻咽癌中的疗效与毒性。结果显示DP-IMRT组完全缓解率更高,3年局部无失败生存、区域无失败生存、无远处转移生存、无病生存和总生存均显著改善,且未增加急性和晚期毒性。

要点

  • PET/CT引导DP-IMRT可提高局部晚期鼻咽癌的完全缓解率和生存获益。
  • DP-IMRT未增加急性和晚期毒性反应。
  • 剂量绘画是LFFS和DFS的独立预后因素。

核心结论

  • FDG-PET/CT引导DP-IMRT联合化疗在局部晚期鼻咽癌中与生存获益相关,且不增加毒性。

研究设计与样本

  • 2012年至2014年纳入213例III-IVB期鼻咽癌患者,接受放化疗,其中PET/CT引导DP-IMRT组101例,CT引导IMRT组112例。

主要发现

  • 完全缓解率在DP-IMRT组为99.0%(100/101),CT引导IMRT组为92.9%(104/112),P=0.037。
  • 3年局部无失败生存率分别为98.8%和91.3%,P=0.032。
  • 3年区域无失败生存率分别为97.2%和91.2%,P=0.049。
  • 3年无远处转移生存率分别为92.9%和87.4%,P=0.041。
  • 3年无病生存率分别为87.9%和82.4%,P=0.02;总生存率分别为91.8%和82.6%,P=0.049。

关键数值与推荐

  • DP-IMRT组中,GTVnx-PET定义为PET图像上鼻咽部大体肿瘤体积内SUV50%max等值线,T1-2期剂量提升至DT 75.2 Gy/32次,T3-4期提升至DT 77.55 Gy/33次。
  • CT引导IMRT组PGTVnx照射剂量为DT 70.4-72.6 Gy/32-33次,每次2.2 Gy。

临床怎么用

  • 对于局部晚期鼻咽癌,可考虑采用FDG-PET/CT引导的剂量绘画IMRT联合化疗以改善生存。
  • 需注意该研究为单中心非随机对照设计,进一步随机试验尚在进行中。

局限性

  • 需要进一步随机试验来全面评估PET/CT引导DP-IMRT的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)-guided dose-painting intensity-modulated radiation therapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) is unclear. This study aimed to assess the efficacy and toxicity of such combination. METHODS: From 2012 to 2014, 213 patients with stage III-IVB NPC received chemoradiotherapy by PET/CT-guided DP-IMRT (group A, n = 101) or CT-based IMRT (group B, n = 112). In group A, subvolume GTVnx-PET (gross tumor volume of nasopharynx in PET images) was defined within GTVnx (gross tumor volume of nasopharynx) as the SUV50%max isocontour; the dose to GTVnx-PET was escalated to DT 75.2 Gy/32 and 77.55 Gy/33 Fx, respectively, for patients with T1-2 and T3-4 disease, respectively. In group B, PGTVnx was irradiated at DT 70.4-72.6 Gy/32-33 Fx in 2.2 Gy per fraction. RESULTS: Complete response rates were 99.0% (100/101) and 92.9% (104/112) in groups A and B, respectively (P = 0.037). Compared with CT-based IMRT, FDG-PET/CT guided DP-IMRT significantly improved 3-year local failure-free survival (LFFS, 98.8% vs. 91.3%; P = 0.032), locoregional failure-free survival (LRFFS, 97.2 vs. 91.2%; P = 0.049), distant metastasis-free survival (DMFS, 92.9% vs. 87.4%; P = 0.041), disease free survival (DFS, 87.9% vs. 82.4%; P = 0.02), and overall survival (OS, 91.8% vs. 82.6%; P = 0.049). No statistically significant differences in acute and late toxic effects were observed. Multivariate analysis showed that dose painting (PET/CT-guided DP-IMRT vs CT-based IMRT without DP) was a significant independent prognostic factor for LFFS and DFS. CONCLUSION: FDG-PET/CT guided DP-IMRT plus chemotherapy is associated with a considerable survival benefit, without increasing toxicity in patients with locoregional advanced NPC. Further randomized trials are needed to fully assess the role of PET/CT-guided DP-IMRT.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liu F, Xi XP, Wang H, et al. PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma. Radiat Oncol. 2017. PMID: 28587681. doi:10.1186/s13014-016-0739-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。